Contineum Therapeutics (NASDAQ:CTNM) Stock Gets Downgrade from Wall Street Zen

Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Saturday, Wall Street Zen reports.

Several other research firms also recently weighed in on CTNM. JonesTrading lifted their target price on Contineum Therapeutics from $24.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, October 15th. Royal Bank Of Canada upped their price target on shares of Contineum Therapeutics from $22.00 to $23.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Stifel Nicolaus set a $23.00 price target on shares of Contineum Therapeutics in a research note on Wednesday, November 4th. Morgan Stanley decreased their price objective on shares of Contineum Therapeutics from $18.00 to $17.00 and set an “equal weight” rating for the company in a report on Monday, September 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Thursday, October 15th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $21.40.

Read Our Latest Analysis on CTNM

Contineum Therapeutics Stock Performance

Shares of CTNM stock opened at $9.86 on Friday. Contineum Therapeutics has a 52-week low of $6.72 and a 52-week high of $17.78. The firm has a market capitalization of $387.20 million, a P/E ratio of -5.57 and a beta of 1.08. The stock has a 50 day moving average price of $11.28 and a 200 day moving average price of $13.41.

Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.04). As a group, sell-side analysts forecast that Contineum Therapeutics will post -1.76 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC grew its position in shares of Contineum Therapeutics by 11.7% during the 1st quarter. Janus Henderson Group PLC now owns 2,734,836 shares of the company’s stock worth $35,594,000 after buying an additional 285,857 shares in the last quarter. Versant Venture Management LLC raised its holdings in shares of Contineum Therapeutics by 138.2% in the third quarter. Versant Venture Management LLC now owns 1,292,628 shares of the company’s stock valued at $17,347,000 after acquiring an additional 750,000 shares in the last quarter. HighVista Strategies LLC purchased a new stake in Contineum Therapeutics in the third quarter worth about $2,923,000. Wellington Management Group LLP lifted its stake in Contineum Therapeutics by 171.2% in the second quarter. Wellington Management Group LLP now owns 150,797 shares of the company’s stock worth $2,472,000 after acquiring an additional 95,188 shares during the period. Finally, Eversept Partners LP lifted its stake in Contineum Therapeutics by 6.5% in the first quarter. Eversept Partners LP now owns 146,411 shares of the company’s stock worth $1,912,000 after acquiring an additional 8,918 shares during the period.

Contineum Therapeutics Company Profile

(Get Free Report)

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for neurological, inflammatory and fibrotic diseases. The company is based in San Diego, California, and was previously known as Pipeline Therapeutics. Its development programs include PIPE-307, an investigational M1 receptor antagonist being studied for neurological conditions, including relapsing-remitting multiple sclerosis. Contineum is also developing PIPE-791, an investigational LPA1 receptor antagonist for fibrotic lung diseases and related conditions.

See Also

Analyst Recommendations for Contineum Therapeutics (NASDAQ:CTNM)

Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.